Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy (CROSBI ID 200926)

Prilog u časopisu | stručni rad

Bacalja, Jasna ; Ulamec, Monika ; Rako, Duje ; Bošković, Lidija ; Trnski, Davor ; Vrdoljak, Eduard ; Krušlin, Božo Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy // In vivo (Athens), 27 (2013), 3; 545-549

Podaci o odgovornosti

Bacalja, Jasna ; Ulamec, Monika ; Rako, Duje ; Bošković, Lidija ; Trnski, Davor ; Vrdoljak, Eduard ; Krušlin, Božo

engleski

Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy

A 48-year-old male underwent a routine ultrasound examination. A tumour mass in the urinary bladder was found and a transurethral biopsy was performed. Pathohistological examination revealed MALT lymphoma. Results of computed tomographic scan, positron emission tomography scan and bone marrow biopsy defined the tumour as primary malignant lymphoma of the urinary bladder. The patient received eight cycles of chemo- immunotherapy (CHOP) and radiotherapy. Five months after therapy, there is a partial radiological remission, but with metabolic progression of the tumour. To our knowledge, this is the first case of MALT lymphoma of the urinary bladder with chemo-immunotherapy and radiotherapy resistance.

CHOP; MALT lymphoma; chemotherapy; rituximab; urinary bladder

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

27 (3)

2013.

545-549

objavljeno

0258-851X

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost